Dr. Jeremy Barton joined Biotheryx as Acting Chief Medical Officer in August 2023. He is responsible for the Company’s program development activities, including clinical and non-clinical operations, regulatory affairs and medical strategy. Dr. Barton has over 30 years of global oncology drug development experience. He previously served as Chief Medical Officer of Biogen (formerly Biogen Idec), eFFECTOR Therapeutics and Mirati Therapeutics. Prior, he worked at Pfizer as Head of Oncology, Biotechnology Clinical Development, overseeing the transition of all oncology compounds from research through investigational new drug applications to proof of concept studies. Dr. Barton holds an M.S. in physiological sciences from Oxford University and an M.D. from University College Hospital Medical School in London. He trained in internal medicine and clinical oncology in the United Kingdom and practiced for 11 years in the National Health Service. Dr. Barton is Board Certified in internal medicine and clinical oncology, a member of the Royal College of Physicians in the United Kingdom, a fellow of the Royal College of Radiologists and a member of the Faculty of Pharmaceutical Medicine.

• 

  Acting Chief Medical Officer in Biotheryx

  Degrading proteins. Saving lives.